Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

NCRI 2016 | Future directions for APOBEC studies

Reuben Harris • 6 Nov 2016
NCRI 2016
Breast Cancer Gastrointestinal Cancer Genitourinary Cancer Gynecological Cancer Lung Cancer Prostate Cancer Skin Cancer

Reuben Harris, PhD of University of Minnesota, Minneapolis, MN discusses future directions for APOBEC studies. Dr Harris’ laboratory is interested in understanding the APOBEC mechanism in order to reveal some clinical vulnerabilities. In addition, Dr Harris collaborates with others to target evolvability and shut off APOBEC-3B or APOBEC-3H to ultimately slow down tumor mutation rate and improve clinical outcomes. Recorded at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.

More from Reuben Harris

0:35
Occurence of APOBEC mutagenesis in human cancers
Reuben Harris • 6 Nov 2016
2:58
APOBEC enzymes contribute to cancer mutagenesis
Reuben Harris • 6 Nov 2016
1:45
Clinical impact of APOBEC enzymes
Reuben Harris • 6 Nov 2016
0:55
APOBEC-3B, a candidate biomarker for response to therapy
Reuben Harris • 6 Nov 2016

Related Videos

1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
The content of VJOncology is intended for healthcare professionals